In recent years, two histone deacetylase (HDAC) inhibitors, romidepsin and belinostat, were approved by the US Food and Drug Administration for the treatment of refractory or relapsed PTCL. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.